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Rheumatoid arthritis (RA) is an autoim-
mune disorder of unknown etiology.
In industrialized countries, rheumatoid
arthritis aﬀects 0.5–1.0% of adults, with
5–50 new cases per 100,000 annually
[1]. RA not only induces disability that
aﬀects physical function, but also results
in premature death. Patients with RA
have a poor life prognosis and a substan-
tially shorter life expectancy compared
to the general population [2]. Therefore,
the development of an eﬀective thera-
peutic strategy focusing on prevention
and treatment of the disease, its com-
plications, and associated disorders is
imperative.
Methotrexate (MTX), which has been
used for more than 40 years in the treat-
mentof rheumatoid arthritis, has ananti-
inﬂammatory cytotoxic and immuno-
suppressive eﬀect. Currently, a small
dose of intermittent medication is the
standard treatment for RA, with proven
eﬃcacy and safety. The therapeutic
mechanisms of MTX in RA have yet
to be fully elucidated. The plasma half-
life of MTX was 7 to 10 h, onset time 6
to 8 weeks, and the optimal therapeutic
eﬀect was seen after 2 to 3 months [3,
4]. MTX administrated twice weekly,
according to the half-life of MTX, was
better than once weekly. However, the
pilot study of Pandya has conﬁrmed
that the beneﬁt was similar in either
approach [5]. An uncontrolled trial
conducted by To et al. suggested that
MTX chronotherapy can improve RA
symptoms compared to the current stan-
dard dosing methods [14]. Therefore,
current clinical approaches involve oral
or intramuscular injection of MTX once
weekly and 12 h of continuous therapy
twice or three times a week. The ﬁrst
approach is widely accepted, owing to
high patient compliance and ﬂexibility.
In recent years, inﬂammatory cy-
tokines such as tumor necrosis factor-α
(TNF-α) and interleukin 6 (IL-6) have
been observed in the blood and synovial
ﬂuid of humans, with excessive produc-
tion of these cytokines implicated in the
pathogenesis of RA [6, 7]. The levels
of inﬂammatory cytokines increased in
the early morning in RA patients, with
a clear circadian rhythm in the blood
[8–10]. Chronotherapy is deﬁned as the
administration of medication based on
biological rhythms in order to optimize
therapeutic outcomes and/or control
adverse eﬀects. RA chronotherapy has
been researched basically and clinically
with glucocorticoids [11, 12], MTX [13,
14], tacrolimus [15], andmizoribine [16,
17]. The results showed that selection
of the optimal dosage associated with
a circadian rhythm of RA symptoms
resulted in an eﬀective treatment for RA.
Inviewof theseﬁndings,wedecidedto
investigate methotrexate chronotherapy
using a collagen-induced arthritis (CIA)
ratmodel immunizedwith bovine type II
collagen. In this study, serum IL-6 lev-
els were measured at six diﬀerent time
points. MTX was administered at two
diﬀerent dosing intervals based on these




Six-week-old, female Wister rats weigh-
ing 160 to 170 g each were purchased
from the Experimental Animal Center
of Shandong (Shandong, China). The
study was conducted at Bin Zhou (Shan-
dong, China). They were housed 6 in
each cage under standardized light-dark
cycle conditions (lights-on and lights-oﬀ
at 07:00 and 19:00 h, respectively) at a
room temperature of 24 ± 1 °C and a hu-
midity of 60 ± 10% with free access to
food and water. Experiments were con-
ducted after formal approval by the Insti-
tutional Ethical Committee for Research
on Animals.
Reagents
The reagents included bovine collagen
type II (CII) and complete Freund’s
adjuvant (CFA; Chondrex, Washing-
ton, USA), as well as MTX (Shanghai
Sine Pharmaceutical Co., Ltd., Shanghai,
China). Enzyme-linked immunosorbent
assay (ELISA) kits of TNF-α, IL-6, and
CRP (R&D system, Minnesota, USA)
were purchased. All the other chemi-




Fig. 19 Interleukin 6 (IL-6)
levels of rats after initial
immunization. The IL-6
levels in collagen-induced
arthritis (CIA) rats increased
after immunization and
peakedonday 21 (a). Circa-
dian rhythmsofplasma IL-6
in normal (n=5) andCIA







Bovine collagen type II (CII) was dis-
solved in 0.05 mol/L acetic acid at
2 mg/ml and emulsiﬁed in an equal
volume of CFA. Rats were immunized
intracutaneously with 200 μl of the
emulsion divided into four points along
the dorsal spine symmetrically. Seven
days later, a similar amount of bovine
CII emulsiﬁed into CFA was injected
intracutaneously as a booster dose.
Evaluation of arthritis
The severity of CIA was assessed using
a scoring system [18]. The disease sever-
ity was recorded for each limb as fol-
lows: score 0, normal; 1, erythema and
mild swelling conﬁned to the midfoot
(tarsals) or ankle joint; 2, erythema and
mild swelling extending from the ankle
to the midfoot; 3, erythema and mod-
erate swelling extending from the ankle
to the metatarsal joint; and 4, erythema
and severe swelling of the ankle, foot,
and digits. The clinical arthritis score
was deﬁned as the sum of the scores of
all four paws of each rat. Evaluation was
completed by two experimenters inde-
pendently. Final score included the av-
erage of the two scores. Arthritis index
(AI) represented the total joint score. The
model was successful when the AI was
equal to or greater than 4.
Groups and treatment
Wistar rats were divided randomly into
ﬁve groups (n = 8 per group): the 6 hours
after the lightwas turned on (HALO) and
the 18 HALO experimental groups, the
qw positive controls, the PBS negative
controls, and the normal control group.
MTX (1/7 mg/kg) was administered at
6 HALO when the IL-6 level started to
decrease and at 18 HALO when the IL-
6 level started to increase, once daily by
gastric perfusion, separately from day 1
to day 56 after successful modeling. In
the qw (once a week) positive control
group, MTX (1 mg/kg) was adminis-
tered once weekly by gastric perfusion.
The PBS control and the normal groups
were given an equal volume of phosphate
buﬀer saline (PBS) simultaneously.
IL-6 level after initial immunization
IL-6 levels of the rats were measured on
days 0, 7, 14, 21, 28, and 35 for signs
of arthritis between days 1 and 36 after
initial immunization. Blood was drawn
from the caudal vein of CIA rats (n = 5)
ondays 0, 7, 14, 21, 28, and 35 after initial
immunization. Serum was obtained by
centrifugationat 3000 rev/min for 10min
and frozen at –80 °C until assay. We
measured IL-6 levels using an ELISA kit.
24-hour rhythm in serum IL-6
levels
On day 21 after immunization, blood
was collected at six diﬀerent times (2,
6, 10, 14, 18, or 22 HALO) in normal
(n = 5) or untreated CIA (n = 8) rats, and
centrifuged immediately at 3000 rpm for
10 min. Serum was obtained and stored
at –20 °C until analyzed.
Inﬂuence of MTX chronotherapy
on arthritis score
The rats were assessed every 3 days for
signs of arthritis between days 1 and 56
after immunizationusing the scoring sys-
tem [18].
Measurement of serum TNF-α, IL-
6, and CRP level
Blood was collected and serum was ob-
tained by centrifugation at 3000 rpm for
10 min and stored at –80 °C prior to
analysis. Serums IL-6 levels were quan-
tiﬁed by ELISA.The same procedure was
used to assay TNF-α and CRP with the
cytokine-speciﬁc antibodies.
Histological analysis
On day 56, all rats were sacriﬁced via
anesthesia after serum collection. The
ankle joints were removed from the rats
for histological examination. The joints
were ﬁxed in 10% phosphate-buﬀered
formalin, decalciﬁed in 10% EDTA for
30 days at 4 °C, and then embedded in
paraﬃn. Serial paraﬃn sections (5 mm
thick)were stainedwithhematoxylin and
eosin (H&E). Pathological sections were
examined and graded for inﬂammation,
pannus formation, cartilage damage,
and bone resorption microscopically,
and scored using histopathology scoring
criteria [19].
Leukocyte count analysis
On day 56, blood samples were drawn
from the inferior vena cava and leuko-
cyte counts of the rats were performed
immediately after blood drawing.
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Role of methotrexate chronotherapy in collagen-induced rheumatoid arthritis in rats
Abstract
Aim. To explore the circadian rhythm
of serum interleukin (IL)-6 in collagen-
induced arthritis (CIA) rats and compare the
safety and eﬀectiveness of methotrexate
(MTX) administered traditionally and via
chronotherapy.
Methods. CIA rat models were immunized
with bovine type II collagen. Serum IL-6 levels
in normal and CIA rats were measured at
2, 6, 10, 14, 18, or 22 h after the light was
turned on (HALO). MTX was administered
to 6 HALO/18 HALO experimental groups of
Wistar rats once daily according to the IL-6
rhythm. The control groups (positive, negative,
and normal) were given MTX or an equal
volume of phosphate buﬀered saline (PBS)
once a week simultaneously. Arthritis score,
tumor necrosis factor (TNF)-α, interleukin
(IL)-6, and C reactive protein (CRP) levels in
the serum were measured by enzyme-linked
immunosorbent assay (ELISA). Histological
changes in the ankle joint were analyzed.
Results. After 6 weeks of treatment, arthritis
scores in the experimental group were lower
than in the control group. The expression of
TNF-α, IL-6, and CRP was lower in the 18 HALO
group than in the control or 6 HALO groups.
Histopathology scores in the experimental
groups were lower than in the control group
(p < 0.05).
Conclusion. The plasma IL-6 levels in CIA
rats were higher than in normal rats and
showed signiﬁcant circadian rhythm. Daily
administration of MTX is more potent than
weekly administration. The therapeutic index
of rheumatoid arthritis (RA) may be improved
with MTX therapy based on the IL-6 circadian
rhythm.
Keywords
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Bedeutung der Methotrexat-Chronotherapie bei kollageninduzierter rheumatoider Arthritis von
Ratten
Zusammenfassung
Ziel der Arbeit. Ziel war es, den zirkadianen
Rhythmus von Interleukin-6 (IL-6) im Serum
von Rattenmit kollageninduzierter Arthritis
(CIA) zu untersuchen sowie die Sicherheit
und Wirksamkeit von Methotrexat (MTX) bei
herkömmlicher Gabe und per Chronotherapie
zu vergleichen.
Methoden. Als Modell der CI dienende Ratten
wurden mit Kollagen vom bovinen Typ II
immunisiert. Die Serumspiegel von IL-6
wurden bei normalen und CIA-Ratten 2, 6, 10,
14, 18 oder 22 h nach Einschalten des Lichts
(HALO) gemessen. Den Wistar-Ratten in den
Versuchsgruppen 6 HALO/18 HALO wurde
einmal täglich MTX entsprechend dem IL-6-
Rhythmus verabreicht. Gleichzeitig wurde den
Kontrollgruppen (positiv, negativ und normal)
einmal pro Woche MTX oder das gleiche
Volumen phosphatgepuﬀerter Salzlösung
(„phosphate buﬀered saline“, PBS) gegeben.
Ermittelt wurden der Arthritis-Score sowie
die Serumspiegel von Tumornekrosefaktor-
alpha (TNF-α), IL-6 und C-reaktivem Protein
(CRP) anhand der Messung mittels ELISA-
Test („enzyme-linked immunosorbent
assay“). Außerdem wurden histologische
Veränderungen im Fußgelenk untersucht.
Ergebnisse. Nach 6-wöchiger Therapie waren
die Arthritis-Scores in der Versuchsgruppe
niedriger als in der Kontrollgruppe. Die
Expression von TNF-α, IL-6 und CRP war in
der Gruppe 18 HALO geringer ausgeprägt
als in der Kontrollgruppe und der Gruppe
6 HALO. Darüber hinaus waren die histopa-
thologischen Werte in den Versuchsgruppen
niedriger als in der Kontrollgruppe (p < 0,05).
Schlussfolgerung. Die Werte für IL-6 im
Plasma waren bei CIA-Ratten höher als bei
normalen Ratten und wiesen einen signiﬁkant
ausgeprägten zirkadianen Rhythmus auf.
Dabei stellte sich die tägliche Gabe von MTX
als wirksamer heraus denn die wöchentliche
Verabreichung. Der therapeutische Index
bei rheumatoider Arthritis (RA) lässt sich
möglicherweise mit einer MTX-Therapie
verbessern, die auf dem zirkadianen Rhythmus
von IL-6 basiert.
Schlüsselwörter
Cytokin · Biorhythmus · Entzündung ·
Behandlung · Histopathologie
Statistical analysis
The results were analyzed using a sta-
tistical program SPSS/PC+, version 13.0
(SPSS Inc, Chicago, IL, USA). One-
way analysis of variance (ANOVA) and
repeated-measures ANOVA were used
to determine the statistically signiﬁcant
diﬀerences between the various exper-
imental groups. Diﬀerences between
groups were determined using Scheﬀe’s
or Fisher’s protected least signiﬁcant
diﬀerence test. Data are expressed as
means ± standard deviation (SD) and
p < 0.05 was considered statistically
signiﬁcant.
Results
Increased IL-6 levels after
immunization and circadian
rhythm of serum IL-6 levels
The IL-6 levels started to increase after
immunizationandpeakedonday21; they
then decreased and eventually returned
to normal levels on day 35 (. Fig. 1a).
Serum IL-6 concentrations in collagen-
induced arthritic rats were higher than
in normal rats on day 21. IL-6 lev-
els showed signiﬁcant circadian rhythms,
with higher levels in 6 HALO and lower
levels in 18 HALO CIA rats (. Fig. 1b).
Serum IL-6 showed no circadian rhythm
in normal rats (p > 0.05).
Eﬀect of MTX chronotherapy on
arthritis score and pathology
changes
In the study, the arthritis scores were as-
sessedineachgroup,whicheachincluded
8 rats. In the normal group, there was no
joint swelling during the whole experi-
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Fig. 28 Inﬂuence ofmethotrexate chronotherapy on arthritis score and ankle joint histopathological changes.Data repre-
sent themean± standarddeviation (n=8). The arthritis scoreswere assessed in eachgroup (a) and suppressedpeak arthritic
severity comparedwith the once aweek (qw) andblank control groupwas seen on day 56 (b).cHistopathology score com-
parisons betweengroups onday 56.Histopathology: dnormal group,e collagen-inducedarthritis rats, fphosphate-buﬀered
saline (PBS) control group,gqw control group,h 6 hours after the lightwas turned on (HALO) experimental group, i 18HALO
experimental group
ment and the arthritis score was zero at
each time point. Rats on days 7–10 after
initial immunization showed congestion
and edema of ankle joints. On days 10 to
16 after initial immunization, the ankles
showed swelling and hyperemia, which
increased by day 21, followed by a grad-
ual decline in joint swelling (. Fig. 2a).
MTX administrated once weekly or once
daily decreased the arthritis score signiﬁ-
cantly (. Fig. 2a). Onday 56, the arthritic
severity in the 6 HALO/18 HALO exper-
imental groups was markedly decreased
compared to the qw and PBS control
groups on day 56 (p < 0.05). The Arthri-
tis score in the 18 HALO experimen-
tal group was obviously decreased com-
pared to the 6HALOexperimental group
(p < 0.05; . Fig. 2b).
Eﬀect of MTX dosing time on
pathology changes
After MTX treatment, histopathology
scores were reduced (p < 0.05) and the
histopathology scores were lower in 6 am
and 18 HALO experimental groups than
in the qwpositive control group (p< 0.05;
. Fig. 2c). The eﬀect ofMTXdosing time
on ankle joint histopathological changes
varied. The normal group of rats showed
normal articular cartilage and absence of
damage in the synovium (. Fig. 2d). The
CIA rats showed marked inﬁltration of
inﬂammatory cells (. Fig. 2e). The PBS
control group showed marked inﬁltra-
tion of inﬂammatory cells and synovial
hyperplasia, and the mean histopathol-
ogy score was 11.7 ± 2.6 (. Fig. 2f). The
qw positive control group was treated
with MTX once a week and the mean
histopathology scores were 9.07 ± 1.98
(. Fig. 2g). The mean histopathology
score in the 6 HALO experimental
group was 7.43 ± 1.28 (. Fig. 2h) while
this was 6.64 ± 1.27 in the 18 HALO
experimental group (. Fig. 2i).
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Fig. 38 Eﬀectofmethotrexatedosingtimeontumornecrosis factor-α (TNF-α), interleukin (IL-6), andCreactiveprotein (CRP)
levels. The (optical density)ODvalueofTNF-α, IL-6, andCRP in the18hours after the lightwas turnedon (HALO)experimental
groupwasmarkedly decreased comparedwith the phosphate-buﬀered saline (PBS) and once aweek (qw) control groups
(p<0.05; a–c). The ODvalues of IL-6 (b) and CRP (c ) in the 18 HALO groupweremarkedly decreased comparedwith those of
the 6 HALO group
Eﬀect of MTX dosing time on TNF-
α, IL-6, and CRP levels
MTX was administered every day at
6 HALO or 18 HALO based on the
circadian rhythm of IL-6 level. The
OD values of TNF-α, IL-6, and CRP
in the 18 HALO experimental group
were markedly decreased compared
with the PBS and qw control groups
(p < 0.05; . Fig. 3). The OD values
of IL-6 (. Fig. 3b) and CRP (. Fig. 3c)
in the 18 HALO group were markedly
decreased compared with those of the
6 HALO group.
Eﬀect of MTX dosing time on
myelosuppression
After MTX treatment, leukocyte counts
were lower in the 6 HALO and 18 HALO
experimental groups than in controls
(. Fig. 4, p < 0.05), but they were still
within the normal range.
Discussion
Rheumatoid arthritis (RA) is a chronic
progressive inﬂammatory disease with
massive inﬁltration of inﬂammatory
cells in the synovium of multiple joints.
Monocytes, T and B lymphocytes, and
ﬁbroblasts produce inﬂammatory cy-
tokines including IL-6, TNF, and other
proinﬂammatory cytokines. These cy-
tokines contribute to RA pathogenesis
and were reduced rhythmically corre-
sponding to major symptoms, such as
pain, inﬂammation, and stiﬀness [12,
20, 21].
TheCIAratmodelmimics certain fea-
tures of RA [22]. It is internationally rec-
ognized for the study of RA. In our study,
we have measured IL-6 levels (. Fig. 1a)
of rats after immunization. We found
that the IL-6 level was relatively high on
day 21. Therefore, in a later study, we
measured the levels of IL-6 at six diﬀerent
time points on day 21. We found that
the level of IL-6 showed a clear 24-hour
rhythm, with higher levels at 6 HALO
and lower levels at 18 HALO in the CIA
rats (. Fig. 1b).
RA is characterizedby synovial hyper-
plasia, pannus formation, and cartilage
and bone destruction in the joint. In our
study, we found that 1 week after im-
munization, the skin of the foot joints
in rats was ﬂushed, with mild swelling.
After 2 weeks, most of the rat ankle joint
was swollen, with shiny skin and limited
joint mobility. After 3 weeks, skin ul-
cers were found in some rats, and joint
swelling and deformation were found af-
ter 5 to 6weeks. In our study, we assessed
the arthritis score of the rats (. Fig. 2a)
and compared the arthritis index of each
group on day 56 (. Fig. 2b). At the end of
the experiment, the rats were sacriﬁced
and the ankle joints were removed for
histological examinationandhistopatho-
logical evaluation by H&E staining. The
ankle joints, cartilage, and joint space
in normal rats were normal. The knee
joints of the CIA rats displayed notable
synovial hyperplasia, inﬂammatory cell
ﬁltration, and partial bone destruction
(. Fig. 2d–i). The scores of the experi-
mental groups were signiﬁcantly lower
than that of the control group (. Fig. 2c).
Studies have shown that treatment based
on circadian rhythms might delay the
progression of pathology.
TNF-α plays an important role in
the pathogenesis of RA. It mediates
inﬂammatory cell inﬁltration, cartilage
destruction, and systemic inﬂammation.
It also induces the synthesis of proin-
ﬂammatory cytokines (such as IL-1 and
IL-6) and chemokines, and activates
macrophages, which in turn perpetu-
ate the inﬂammation in autoimmune
pathology [23, 24]. Plasma TNF-α and
TNF-αmRNA expression showed a clear
circadian rhythm, with peaks 2 h after
the light was turned on inMRL/lpr mice,
leading to an excellent outcome when
MTX was administered under increased
cytokine conditions [13, 14]. Some
researchers have postulated that MTX
reduces plasmaTNF-α level by suppress-
ing transcriptional activity rather than
by suppressing lymphocyte proliferation
[14]. In our study, the levels of plasma
TNF-α were measured. We found that
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Fig. 48 Eﬀect ofmethotrexate dosing time
on leukocyte counts.On day 56, blood samples
were drawn from the inferior vena cava and
leukocyte counts of the ratswere performed
immediately after blooddrawing.Values repre-
sent themean± standard deviation.Leukocyte
countswere lower in 6 hours after the light
was turned on (HALO) and 18HALO experi-
mental groups than in controls (p<0.05), but
are still within the normal range.PBSphos-
phate-buﬀered saline, qw once aweek
the value of TNF-α in the 18 HALO
experimental group was markedly de-
creased compared with the PBS and
qw control groups (p < 0.05; . Fig. 3a).
These results indicate that MTX once
daily is superior to once weekly.
IL-6 is a key proinﬂammatory cy-
tokine in RA. It mediates osteoclast ac-
tivation and ﬁbroblast synovial cell ac-
tivation, thus contributing to synovial
pannus formation, joint destruction, and
bone and cartilage breakdown. In our
study, we demonstrated higher plasma
IL-6 levels in CIA rats than in normal
rats at almost every sampling time, with
a signiﬁcant circadian rhythm indicating
higher levels during the light phase and
lower levels in the dark phase (. Fig. 1b).
Based on the circadian rhythm, we ad-
ministered MTX once daily according to
achronotherapyschedule, inwhichMTX
wasgivenat6HALOor18HALOwithout
altering the dosage. We assessed arthri-
tis score; production of TNF-α, IL-6, and
CRP in serum; and histological changes
of ankle joints. In rats, the arthritis score
was signiﬁcantly lower in the 18 HALO
experimental group than in the control
and 6 HALO experimental groups on
day 24. On day 56, the 18 HALO ex-
perimental group treatment signiﬁcantly
inhibited the increase of arthritis score
compared to the control and 6HALO ex-
perimental groups in rats (. Fig. 3b), and
showed a clear improvement in inﬂam-
matory cytokines. These results indicate
that MTX administered once daily was
better than once weekly, and that MTX
chronotherapy was eﬀective in treating
CIA rats.
CRP is a marker of inﬂammatory
responses. Plasma CRP levels showed
a circadian rhythm, with a peak in
the early morning in RA patients that
matched the rhythms of pain and stiﬀ-
ness [25]. Studies have conﬁrmed that
CRP levels showed a clear circadian
rhythm with a peak at 22 HALO, in
accordance with those seen in CIA and
MRL/lpr mice [13–15]. In our study,
after 8 weeks of treatment, the CRP level
in the 18 HALO experimental group
showed a clear decrease compared to the
qw group (. Fig. 3c). Our study suggests
that MTX once daily has an advantage
over once weekly in terms of eﬃcacy,
and thus the currently used once-weekly
regimen is good enough until alternate
dosing schedules are evaluated in a large
double-blind, randomized, controlled
multicentric trial.
Leukocyte counts increase [26, 27]
in most RA patients and induce an in-
ﬂammatory response. RA symptoms
markedly improved following leukocy-
tapheresis [28]. Leukocyte counts were
measured in MRL/lpr mice and were
found to be signiﬁcantly increased after
RA onset. Circadian variations in the
toxicity of MTX have also been demon-
strated in rats, with maximum toxicity
occurring after dosage at 06:00 h and
minimum toxicity after dosage at mid-
night. Administration at the other two
time points, 12.00 h and 18.00 h, gave
intermediate results [29]. A common
side eﬀect of MTX is leucopenia in RA
patients. In this study, we found that
leukocyte counts decreased in 6 HALO
and 18 HALO experimental groups, but
increased in the qw positive control
group (. Fig. 4). Inhibition of increased
leukocyte counts may be one of the
options available for treatment of RA. In
the current study, we also found a slow
increase in body weight of rats following
treatment, which may account for the
adverse gastrointestinal eﬀects of MTX.
The role of proinﬂammatory cy-
tokines, including TNF-α and IL-6, in
the pathogenesis of RA has led to the
development of biological disease modi-
fying antirheumatic drugs (bDMARDs),
whichspeciﬁcally inhibit these cytokines.
Selecting the optimal therapeutic dosage
based on circadian rhythms of inﬂam-
mation and cytokine response in RA
may result in successful outcomes.
It has been reported in previous stud-
ies that CIA mice administered MTX in
the restingphase showeda larger areaun-
der theplasma concentration–time curve
of MTX than mice administered MTX
in the active phase [13], and that the
daily variations in the pharmacokinetics
of MTX were not related to the dosing-
time dependency of MTX eﬃcacy [14].
From the results of our studies and the
24-hour cycles of cytokines in RA pa-
tients [8, 10], it is thought that MTX has
a signiﬁcantdosing time-dependent anti-
inﬂammatory action and that this eﬀect
may be due to the 24-hour rhythms of
cytokine levels rather than the pharma-
cokinetics of MTX.
Conclusion
This study indicated that plasma IL-6 lev-
els inCIA ratswerehigher than innormal
rats and showed a signiﬁcant circadian
rhythm. The RA therapeutic score may
be improvedbyadministeringMTXonce
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